上海医药拟公开挂牌转让中美施贵宝 30%股权

Group 1 - The core viewpoint of the article is that Shanghai Pharmaceuticals plans to optimize its investment structure by publicly transferring its 30% stake in Celgene Corporation through a public listing, with a minimum listing price of approximately RMB 1.023 billion [1] Group 2 - The transfer process will involve a public listing and must complete relevant state-owned asset evaluation management procedures [1] - The final transfer price will be determined based on the results of the public listing [1]